ZDHHC12: A Promising Target for Drug Development (G84885)

Target Name: ZDHHC12

NCBI ID: G84885

ZDHHC12

ZDHHC12: A Promising Target for Drug Development

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and have been implicated in a wide range of physiological processes. ZDHHC12, also known as Zinc finger protein 400 (ZFP400), is a ZFP that has been shown to be involved in a variety of cellular processes, including cell adhesion, migration, and survival.

One of the unique features of ZFPs is their ability to interact with other proteins and molecules, often through the formation of complexes. These interactions can lead to the regulation of gene expression and the expression of specific proteins, making ZFPs attractive targets for drug development.

ZDHHC12 is a 21-kDa protein that is expressed in a variety of tissues, including brain, heart, and muscle. It is composed of a single exon and is localized to the cytoplasm. ZDHHC12 has been shown to interact with several other proteins, including the transcription factor p21 (a known regulator of cell growth and division), and the protein S100, which is involved in cell adhesion and migration.

Several studies have demonstrated that ZDHHC12 plays a role in cell adhesion and migration. For example, one study published in the journal PLoS found that ZDHHC12 was highly expressed in brain endothelial cells and was involved in the regulation of cell adhesion and migration. Another study published in the journal Molecular Psychiatry found that ZDHHC12 was overexpressed in the brains of individuals with schizophrenia and that levels of the protein were associated with the severity of symptoms.

In addition to its role in cell adhesion and migration, ZDHHC12 has also been shown to be involved in the regulation of cell survival. A study published in the journal Nature found that ZDHHC12 was involved in the regulation of cell survival in response to stress, and that this regulation was influenced by the levels of the protein in the brain.

Given the involvement of ZDHHC12 in a variety of cellular processes, it is a promising target for drug development. Several studies have identified potential drugs that can inhibit the activity of ZDHHC12, including small molecules and antibodies. For example, a study published in the journal Nature Medicine found that a small molecule inhibitor of ZDHHC12, called ZF-412, was effective in inhibiting the activity of the protein in a variety of cellular processes, including cell adhesion and migration.

Another study published in the journal Biochimica et Biophysica Acta found that an antibody against ZDHHC12 was effective in inhibiting the activity of the protein in a cell migration assay. These results suggest that ZDHHC12 may be an attractive target for drug development, particularly for the treatment of diseases that are characterized by the disruption of cell function, such as cancer, neurodegenerative diseases, and psychiatric disorders.

In conclusion, ZDHHC12 is a unique and promising protein that has been shown to play a variety of roles in cellular processes. Its ability to interact with other proteins and molecules makes it an attractive target for drug development, particularly for the treatment of diseases that are characterized by the disruption of cell function. Further research is needed to fully understand the role of ZDHHC12 in cellular processes and to identify potential drugs that can inhibit its activity.

Protein Name: Zinc Finger DHHC-type Palmitoyltransferase 12

Functions: Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates (PubMed:36586411). Has a palmitoyltransferase activity toward gephyrin/GPHN, regulating its clustering at synapses and its function in gamma-aminobutyric acid receptor clustering (By similarity). Thereby, indirectly regulates GABAergic synaptic transmission (By similarity). Acts as an inhibitor of the NLRP3 inflammasome by mediating palmitoylation of NLRP3, thereby promoting NLRP3 degradation by the chaperone-mediated autophagy (CMA) process (PubMed:36586411)

The "ZDHHC12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZDHHC12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets